Table 1 Clinical overview of the BWS-WT cohort.
From: Cancer predisposition signaling in Beckwith-Wiedemann Syndrome drives Wilms tumor development
Sample ID | BWS subtype in blood, kidney tumor | Sex | Age at WT diagnosis (months) | Laterality | Histology | Stage | Months off therapy | Outcome | Clinical score |
|---|---|---|---|---|---|---|---|---|---|
Patient 1 (WT8/NT8) | pUPD11 | M | 26 | Unilateral | Favorable | 3 | 4 | Alive | 4 |
Patient 2 (WT9) | pUPD11 | M | 0 | Unilateral | Favorable | Unk | 57 | Alive | 3 |
Patient 3 (WT10) | pUPD11 | M | 44 | Bilateral | Favorable | 5a | 38 | Alive | 3 |
Patient 4 (WT11/NT11) | IC1 GOM | M | 45 | Unilateral | Unfavorable | 4 | 40 | Alive | 4 |
Patient 5 (WT12/NT12) | pUPD11 | F | 41 | Unilateral | Unfavorable | 2 | 37 | Alive | 3 |
Patient 6 (WT13/NT13) | IC1 GOM | F | 109 | Unilateral | Favorable | 3 | N/A | Deceased | 3 |
Patient 7 (WT14) | pUPD11 | M | 11 | Bilateral | Favorable | 5 | On therapy | N/A | 4 |
Patient 8 (WT15/NT15) | IC1 GOM | F | 34 | Bilateral | Favorable | 5 | N/A | Deceased | 2 |
Patient 9 (WT16/NT16) | pUPD11 | F | 5 | Bilateral | Favorable | 5 | 12 | Alive | 4 |
